5 results
To investigate the efficacy, safety, and pharmacokinetics of volasertib in combination with low-dose cytarabine versus investigator*s choice of anti-leukemic treatment in patients with relapsed or refractory acute myeloid leukemia with no…
The effect of rLH for controlled ovarian hyperstimulation in order to achieve an increase of 10% in top quality embryos.
The objective is to define the maximum tolerable dose (MTD) by evaluation of dose-limiting toxicity (DLT) of volasertib in paediatric leukaemia and solid tumours in the age group 2 to less than 12 and 12 to less than 18 years. A further objective is…
What is the level of agreement between the gold standard, which includes invasive DO2 and VO2 measurements (with pulmonary artery catheter and central venous line), when compared with DO2 and VO2 measurements derived by a minimal invasive approach (…
To investigate the efficacy, safety, and pharmacokinetics of intravenous volasertib + subcutaneous low-dose cytarabine in patients * 65 years of age with previously untreated acute myeloid leukaemia, ineligible for intensive remission induction…